LG Chem is the first to receive WHO prequalification for the sIPV vaccine
LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021
BILTHOVEN, the Netherlands, Jan. 21, 2021 /PRNewswire/
Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV) vaccine Eupolio™, developed by Intravacc and out-licensed to South Korean LG Chem in 2014. The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.
Eupolio™ received the prequalification status from the World Health Organization (WHO) by the end of December. LG Chem signed a contract with UNICEF to supply $80 million worth of polio vaccine Eupolio™ from 2021 to 2022. The company will supply the vaccine to 70 countries in the Middle East, Africa and Southeast Asia starting in January 202
Share this article
Share this article
- Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease
- First dosing of PRV-101 in the PROVENT Phase I clinical trial started in January 2021
BILTHOVEN, Netherlands, Jan. 19, 2021 /PRNewswire/
Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in human Phase I clinical study called PROVENT (PROtocol for coxsackievirus Vaccine in healthy volunteers) .
Provention Bio is clinical stage biopharmaceutical company, that selected Intravacc in 2018 to lead product development and manufacturing of clinical study material for Provention s vaccine candidate (PRV-101). This CVB vaccine candidate is developed for the intended prevention of acute CVB infection and
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
- First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
- Evaluation of Cristal s CliCr® and Intravacc s OMV technology
News provided by
Share this article
, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a strategic collaboration to develop novel vaccine programs against human diseases with the initial candidate targeting COVID-19.
(PRNewsfoto/Intravacc B.V.)
Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac
Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
Costs for conversion of Ordinary Shares into ADS s waived by JP Morgan Chase for initial four weeks after today
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today separately announced that in connection with the listing of American Depositary Shares ( ADSs ) representing ordinary shares of nominal value of €0.01 each in the capital of the Company ( Ordinary Shares ) on the Nasdaq Global Market ( Nasdaq ), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs will begin tra
Each ADS represents 10 ordinary shares
The Company s ordinary shares continue to trade on Euronext Amsterdam
No new shares issued in connection with the Nasdaq listing
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ( ADSs ) have been admitted for listing on the Nasdaq Global Market ( Nasdaq ) under the symbol PHAR and will begin trading tomorrow; Wednesday 23 December. Each ADS represents 10 of the Company s ordinary shares of €0.01 nominal value ( Ordinary Shares ).
The United States Securities and Exchange Commission ( SEC ) has also declared effective the Company s registration statements on Form F-1 and Form F-6, each filed with the SEC.